Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Announces strategic clinical trial plans for tecarfarin in patients with End-Stage Kidney Disease (ESKD) transitioning to dialysis Tecarfarin can potentially address critical treatment gaps in patients with ESKD Pivotal step forward in pursuit of ESKD +